...
首页> 外文期刊>Scientia pharmaceutica >Carbopol/Chitosan Based pH Triggered In Situ Gelling System for Ocular Delivery of Timolol Maleate
【24h】

Carbopol/Chitosan Based pH Triggered In Situ Gelling System for Ocular Delivery of Timolol Maleate

机译:基于Carbopol /壳聚糖的pH触发的原位胶凝系统,用于马来酸替莫洛尔的眼部递送

获取原文

摘要

The poor bioavailability and therapeutic response exhibited by conventional ophthalmic preparations due to rapid precorneal elimination, dilution and nasolacrimal drainage of the drug may be vanquished by the use of in situ gelling systems that are instilled as drops in to the eye and undergo a sol-gel transition in the cul-de-sac. Timolol eye drops may cause systemic side effects in glaucoma patients due to absorption of the drug into systemic circulation. In situ gelling system of this drug can provide localized effect with reduced contraindications, improved patient compliance and better therapeutic index. The present work describes the formulation and evaluation of an ophthalmic delivery system of an antiglaucoma drug, timolol maleate (TM) based on the concept of pH-triggered in situ gelation. Polyacrylic acid (carbopol) was used as the gelling agent in combination with chitosan (amine polysaccharide), which was acted as a viscosity-enhancing agent. Formulations were evaluated for pH, viscosity, gelling capacity and drug content. The 0.4% w/v carbopol/0.5% w/v chitosan based in situ gelling system was in liquid state at room temperature and at the pH formulated (pH 6.0) and underwent rapid transition into the viscous gel phase at the pH of the tear fluid (lacrimal fluid) (pH 7.4). The in vitro drug release and in vivo effects of the developed in situ gelling system were compared with that of Glucomol? (a 0.25% TM ophthalmic solution), 0.4% w/v carbopol solution as well as liposomal formulation. The results clearly demonstrated that developed carbopol-chitosan based formulation was therapeutically efficacious and showed a fickian (diffusion controlled) type of release behaviour over 24 h periods. The developed system is thus a viable alternative to conventional eye drops and can also prevent the rapid drainage as in case of liposomes.
机译:常规眼科制剂由于快速的角膜前清除,稀释和鼻泪引流而表现出的不良生物利用度和治疗反应,可以通过使用原位胶凝系统加以解决,该系统可滴入眼中并通过溶胶凝胶进行滴注死胡同中的过渡。由于药物吸收到全身循环中,替莫洛尔滴眼液可能在青光眼患者中引起全身性副作用。该药物的原位胶凝系统可在减少禁忌症,改善患者依从性和更好的治疗指数方面提供局部效果。本工作基于pH触发原位凝胶化的概念,描述了抗青光眼药物马来酸替莫洛尔(TM)的眼科给药系统的配方和评估。聚丙烯酸(carbopol)与用作增粘剂的壳聚糖(胺多糖)组合用作胶凝剂。评价制剂的pH,粘度,胶凝能力和药物含量。 0.4%w / v的carbopol / 0.5%w / v的壳聚糖原位胶凝体系在室温下和配制的pH值(pH 6.0)下呈液态,在泪液的pH值下迅速转变成粘性凝胶相液体(泪液)(pH 7.4)。将已开发的原位胶凝系统的体外药物释放和体内作用与葡糖醇? (0.25%TM眼药水),0.4%w / v卡波姆溶液以及脂质体制剂。结果清楚地表明,开发的基于卡波普-壳聚糖的制剂具有治疗效果,并且在24小时内显示出菲克(扩散控制)类型的释放行为。因此,所开发的系统是常规滴眼剂的可行替代方案,并且还可以防止脂质体情况下的快速引流。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号